BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies

BiondVax (NASDAQ: BVXV), which focuses on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has shown, through an ongoing in vivo preclinical proof-of-concept study, that its lead NanoAb candidate for the treatment of COVID-19 exhibits clear competitive advantages over existing monoclonal antibodies (“mAbs”) and oral therapies. “According to statistically significant results released early January, BiondVax established that its inhaled therapy virtually eliminated the SARS-CoV-2 virus and prevented illness when administered prophylactically… The second set of results, announced January 23, evidenced that when the NanoAb was administered by inhalation three hours before infection, it virtually prevented the hamsters from contracting the illness… BiondVax, which aims to replicate in human trials the efficacy demonstrated so far in its animal studies, believes there will continue to be a strong demand for COVID prophylactics and treatments. This belief is supported by Pfizer’s recent report, suggesting that revenues from COVID products are expected to grow in 2024,” a recent article reads. “Encouragingly, our lead NanoAb candidate, currently being prepared for clinical trials, has demonstrated neutralization of all relevant Omicron subvariants,” BiondVax CEO Amir Reichman is quoted as saying.

To view the full article, visit https://ibn.fm/MwIoG

About BiondVax Pharmaceuticals Ltd.

BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven-country, 12,400-participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.